LABCORP HOLDINGS INC. (LH) Stock
LH has an Alpha Score of 58 out of 100 (moderate), computed on Oct 30, 2026 from 3 of 4 sub-scores. 10 members of Congress disclosed 31 trades in LH since 2015: 18 purchases and 13 sales, most recently April McClain Delaney (sale, Aug 25, 2026). 6 of the hedge funds AlphaScala tracks reported LH in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $63.85M. Company insiders reported 0 open-market buys and 3 sales on SEC Form 4 in the 90 days to Nov 3, 2026. Its trailing P/E ratio is 26.2 and its net margin 7.0% (key statistics as of Oct 22, 2026).
What is LH's Alpha Score?
How it works →Alpha Score of 58 reflects moderate overall profile with strong momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded LABCORP HOLDINGS INC. (LH)?
Most recent: April McClain Delaney (sale, Aug 25, 2026); records start May 27, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| April McClain Delaney D-MD · House | 2026-08-25 | sale | $100k – $250k |
| April McClain Delaney D-MD · House | 2026-08-07 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-08-06 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-08-05 | partial sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-02-11 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-02-04 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2026-01-28 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded LH, with filing lags →Which hedge funds own LH?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 228K | $63.85M | +83% |
| Point72 Steve Cohen | 137K | $38.48M | -47% |
| Marshall Wace | 97K | $27.07M | +2379% |
| D.E. Shaw David Shaw | 40K | $11.21M | NEW |
| Citadel Ken Griffin | 35K | $9.90M | -50% |
| Bridgewater Associates Ray Dalio | 3K | $783.4K | -75% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are LABCORP HOLDINGS INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 30, 26 | Parham Richelle P | Director | SELL | 1.1K | $389K |
| Aug 17, 26 | Anderson Kerrii B | Director | SELL | 3.0K | $954K |
| Aug 11, 26 | Schechter Adam H | President & CEO | SELL | 4.7K | $1.5M |
| Aug 4, 26 | Summy Amy B. | EVP, Chief Marketing Officer | SELL | 924 | $283K |
| Aug 3, 26 | Wilkinson Peter J | SVP, Chief Accounting Officer | SELL | 82 | $25K |
| Aug 3, 26 | Wilkinson Peter J | SVP, Chief Accounting Officer | SELL | 1.3K | $414K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are LH's key statistics?
Key statistics as of Oct 22, 2026
How does LH's valuation compare with the Healthcare sector?
| Metric | LH | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 26.2 | 27.0 | 102 |
| Net margin | 6.99% | 4.64% | 150 |
| Return on equity | 11.57% | 6.41% | 169 |
| Dividend yield (payers) | 1.35% | 1.69% | 52 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
LH price chart
Powered by TradingViewWhat does LABCORP HOLDINGS INC. do?
Labcorp Holdings Inc. is a leading provider of laboratory services, operating through two primary segments: Diagnostics Laboratories and Biopharma Laboratory Services. It delivers a comprehensive array of diagnostic tests, including blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures, and substance-abuse screenings. The company also specializes in advanced esoteric testing, such as gene-based diagnostics, molecular residual disease testing for cancers like breast, lung, and colon, and innovative blood tests to rule out Alzheimer's-related amyloid pathology. Labcorp Holdings Inc. supports physicians, hospitals, pharmaceutical firms, researchers, and patients with routine and complex clinical lab services, including oncology, genomic testing, and digital pathology platforms. These offerings enable clear decision-making in healthcare, from primary care to specialized biopharma research. Headquartered in Burlington, North Carolina, the company maintains an extensive network of patient service centers and collaborations to advance diagnostic efficiency and patient outcomes.